pexidartinib + sirolimus

Plexxikon MOA pexidartinib-sirolimus

Targeted Indication Status Sites link to clinicaltrials.gov

Malignant
Peripheral Nerve
Sheath Tumors

Phase 1/2a

New York, NY
Boston, MA
St. Louis, MO

NCT02584647

These compounds and/or uses are investigational and have not been approved by the FDA or any other regulatory authority for the uses under investigation. Image above depicts proposed targeted pathway of the investigational agent(s) in the targeted indication.

Patwardhan PP et al. Clinical Cancer Research. 2014; 20(12); OF1-13.